Invivyd (IVVD) Free Cash Flow (2021 - 2025)
Invivyd's (IVVD) quarterly Free Cash Flow came in at -$15.6 million in Q4 2025, up 58.42% YoY from -$9.9 million in Q4 2024, and down 89.78% on a QoQ basis from -$8.2 million in Q3 2025.
Invivyd (IVVD) Free Cash Flow (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has 5 years of Free Cash Flow data on file, last reported at -$15.6 million in Q4 2025.
- Quarterly Free Cash Flow rose 58.42% year-over-year to -$15.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$58.3 million (up 65.84% YoY) and the FY2025 annual result came in at -$58.3 million, up 65.84% from the prior year.
- Free Cash Flow fell to -$15.6 million in Q4 2025, from -$8.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$8.2 million in Q3 2025 to a low of -$76.5 million in Q4 2021.
- A 5-year average of -$40.6 million and a median of -$40.4 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 135.83% — and 2025, when it surged 79.2%.
- Tracing IVVD's Free Cash Flow over 5 years: stood at -$76.5 million in 2021, then surged by 31.81% to -$52.2 million in 2022, then fell by 13.53% to -$59.2 million in 2023, then soared by 36.51% to -$37.6 million in 2024, then surged by 58.42% to -$15.6 million in 2025.
- The last three Free Cash Flow figures came in at -$15.6 million (Q4 2025), -$8.2 million (Q3 2025), and -$13.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.64 Mn |
| Dec 31, 2025 | -15.64 Mn |
| Sep 30, 2025 | -8.24 Mn |
| Sep 30, 2025 | -8.24 Mn |
| Jun 30, 2025 | -13.29 Mn |
| Jun 30, 2025 | -13.29 Mn |
| Mar 31, 2025 | -21.12 Mn |
| Mar 31, 2025 | -21.12 Mn |
| Dec 31, 2024 | -37.61 Mn |
| Dec 31, 2024 | -37.61 Mn |
| Sep 30, 2024 | -39.61 Mn |
| Sep 30, 2024 | -39.61 Mn |
| Jun 30, 2024 | -41.52 Mn |
| Jun 30, 2024 | -41.52 Mn |
| Mar 31, 2024 | -51.90 Mn |
| Mar 31, 2024 | -51.90 Mn |
| Dec 31, 2023 | -59.23 Mn |
| Dec 31, 2023 | -59.23 Mn |
| Sep 30, 2023 | -35.25 Mn |
| Sep 30, 2023 | -35.25 Mn |